Please login to the form below

Not currently logged in
Email:
Password:

Lilly/Lupin Indian diabetes partnership

Eli Lilly & Company has entered into a deal with India-based pharmaceutical firm Lupin to market Lilly's Huminsulin range of products for people with diabetes in India and Nepal

Eli Lilly & Company has entered into a deal with India-based pharmaceutical firm Lupin to market Lilly's Huminsulin range of products for people with diabetes in India and Nepal.

Lilly said the deal would double the current customer base for the products, with around 45,000 doctors to be targeted by Lupin. Financial details were not disclosed.

There are currently around 51 million people with diabetes in India, making the country an increasing priority for pharmaceutical companies whose portfolio includes diabetes products. It is estimated there will be 85 million living with the condition in India by 2030.

Eberhard Ludewigs, vice-president, Emerging Markets, Lilly, said: "As our highest priority, diabetes is a clear 'must win' for Lilly emerging markets. This partnership will allow us to change our game in India. We will have a stronger footprint with many more sales representatives promoting our diabetes brands, and this will become a foundation to expand our diabetes business not only for current products, but also for our future pipeline.”

Previous diabetes-related partnerships in India include Sun Pharma and MSD (known as Merck in the US and Canada). In April the companies agreed to co-market MSD's diabetes drugs, sitagliptin and sitagliptin plus metformin in the India.

1st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics